WHIPPANY, N.J.-- (BUSINESS WIRE)--A new ad hoc analysis from the Phase III ARAMIS trial showed 97.2% of men with non-metastatic castration-resistant prostate cancer (nmCRPC) taking NUBEQA ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback